Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $17.88 · Revenue $337.27B · 8 analysts
Est. EPS $5.01 · Revenue $88.27B · 3 analysts
Est. EPS $19.83 · Revenue $353.23B · 7 analysts
Est. EPS $5.07 · Revenue $93.71B · 3 analysts
$2.35 per share
$2.35 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $321.3B | +9.3% | +8.2% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $1.6B | +3.0% | -53.5% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +3.2% | +6.6% | +0.4% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +1.1% | +9.8% | -23.0% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +0.5% | -5.8% | -57.0% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $3.2B | +7.0% | +107.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +1.0% | -2.1% | +91.4% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 712.7% | -30.8% | +5.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 0.90x | +2.8% | -1.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $76.6B | +14.1% | +2.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 7.96 vs 15.94 | -50.1% | 3.94 vs 5.01 | -21.4% |
| Revenue Surprise | $321.3B vs $321.0B | +0.1% | $84.8B vs $88.3B | -4.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Krikorian Lazarus | officer: SVP & Chief Accounting Officer | Common Stock | D | 985 | $325.97 |
| Aug 24, 2026 | Campbell Elizabeth S | officer: Executive Vice President | Common Stock | D | 11,300 | $324.12 |
| Jul 31, 2026 | NALLY DENNIS M | director | Common Stock | A | 113 | $311.34 |
| Jul 31, 2026 | Cooper Ellen | director | Common Stock | A | 97 | $311.34 |
| Jul 31, 2026 | Tyler Lauren M | director | Common Stock | A | 97 | $311.34 |
Operator: Hello, everyone. Thank you for joining us, and welcome to the Cencora Inc. Q3 Fiscal Year 2026 Earnings Call. [Operator Instructions] I will now hand the conference over to Bennett Murphy. Bennett, please go ahead. Bennett Murphy: Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2026 third quarter results. I am Bennett Murphy, Senior Vice President, Investor Relations and Enterprise Productivity. Joining me today are Bob Mauch, President and CEO; and Eva Boratto, Executive Vice President and CFO. On today's call, we will be discussing non-GAAP financial measures. Reconciliations of these measures to GAAP are provided within today's press release, which is available on our website at investors.cencora.com. We've also posted a slide presentation to accompany today's press release on our investor website. During this conference call, we will discuss forward-looking statements about our business and financial expectations on an adjusted non-GAAP basis, including, but not limited to, EPS, operating income and income taxes. Forward-looking statements are based on management's current expectations and are subject to uncertainty and change. For a discussion of key risks and assumptions, we refer you to today's press release and our SEC filings, including our most recent 10-Q. Cencora assumes no obligation to update any forward-looking statements, and this call cannot be rebroadcast without the permission of the company. You have the opportunity to ask questions after today's remarks by management. We ask that you limit your questions to one per participant in order for us to get to as many as possible. With that, I'll turn the call over to Bob. Robert Mauch: Thank you, Bennett. Hi, everyone, and thank you for joining Cencora's fiscal 2026 Third Quarter Earnings Call. To start, I'd like to thank our Cencora team members for their continued commitment to providing valuable solutions for our customers. In our third quarter, we delivered strong results driven by execution across Cencora and investments to advance our specialty positioning and our pharmaceutical-centric strategy. Our business performance drove double-digit adjusted operating income growth and supported by $1 billion of opportunistic share repurchases, we achieved 12% EPS growth in the quarter. We're pleased to be raising our fiscal 2026 EPS guidance, reflecting our confidence in our continued execution and the strength of our portfolio as we close out the fiscal year. I'm very happy Eva Boratto has joined us as Chief Financial Officer. She will provide details on our performance and continued confidence in our short- and long-term expectations. During my remarks today, I'll highlight how our strategy enables us to deliver on our growth priorities. First, our differentiated specialty pharmaceutical platform uniquely positions us to support innovation and patient care across our footprint. Second, through our digital …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Robert Mauch | President, Chief Executive Officer & Director | USD 6,256,009 | — | 1967 | Active |
Eva C. Boratto | Executive Vice President & Chief Financial Officer | USD 2,721,727 | Female | 1967 | Active |
James F. Cleary Jr. | Advisor | USD 2,721,727 | Male | 1963 | Active |
Silvana Battaglia | Advisor | USD 2,721,727 | Female | 1968 | Active |
Elizabeth S. Campbell | Executive Vice President & Chief Legal Officer | USD 2,276,508 | Female | 1975 | Active |
Samantha L. Hammock | Executive Vice President & Chief Human Resources Officer | USD 1,962,939 | Female | 1979 | Active |
Richard Tremonte | EVP and President of U.S. Pharmaceuticals & Animal Health | — | Male | — | Active |
Pawan Singh Verma | Executive Vice President and Chief Data & Information Officer | — | Male | 1977 | Active |
Bennett S. Murphy | Senior VP Of Investor Relations & Enterprise Productivity and Treasury | — | Male | — | Active |
François Mandeville | Executive Vice President and Chief Strategy and M&A Officer | — | Male | — | Active |
Juan Guerra | EVP & President of International Business Group | — | Male | — | Active |
Lazarus Krikorian | Senior Vice President, Chief Accounting Officer & Corporate Controller | — | Male | 1965 | Active |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Shares of Cencora, Inc. (NYSE: COR - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the fifteen research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1-year
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Allspring Growth Fund outperformed the Russell 3000 Growth Index during the quarter. Sandisk Corp. is riding the AI storage super-cycle. Shares of Cencora could not distribute in a 'risk-on' market.
